Volume : 6, Issue : 1, January - 2017

A STUDY OF SERUM POTASSIUM LEVEL IN HYPERTENSIVE PATIENTS TREATED WITH RAMIPRIL VS TELMISARTAN

Gian Chand, Rabinder Kumar, Pritam Singh Sandhu

Abstract :

<p>&nbsp;<span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Hypertension is a major independent risk factor for coronary&nbsp; artery disease, stroke, heart failure, renal&nbsp; failure and peripheral arterial disease.</span><sup style="text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">1</span></sup><span class="apple-converted-space" style="text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</span></span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;">The two major classes of drugs that target the RAAS are the angiotensin converting</span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;"> </span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;">enzyme inhibitors (ACEIs)&nbsp; and the&nbsp; selective&nbsp; angiotensin receptor blockers (ARBs).²</span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;">Hyperkalemia is one of the important side effects of </span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;">ACEIs/ARBs. Our study mainly aims to study serum potassium level and compare efficacy of BP lowering with ramipril and telmisartan in hypertensive patients</span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;"> at baseline, 1 week and 1 month</span><span style="text-align: justify; font-size: 12pt; line-height: 200%; font-family: &quot;Times New Roman&quot;, serif;">. There was significant rise in serum potassium levels from baseline with both drugs but on comparison, no significant rise in serum potassium level was seen. There was significant fall in blood pressure with both drugs but telmisartan was more effective in lowering blood pressure as compared to ramipril.&nbsp;</span></p> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;&#10;line-height:200%;tab-stops:130.5pt"><span style="font-size:12.0pt;line-height:200%;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-fareast-font-family:&quot;Arial Unicode MS&quot;"><o:p></o:p></span></p>